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Aims Direct and indirect costs of ischaemic heart disease
were assessed in Switzerland, for the period 1988-1993, in
order to evaluate the economic consequences of more
intensive treatment of the disease and of the decreasing
mortality from ischaemic heart disease in the working
population.
Methods and Results A societal perspective was taken for
a prevalence-based assessment of the direct (total resources
consumed by outpatients and inpatients) and indirect (due
to morbidity, invalidity, and premature death, using the
human capital approach) costs. The results showed the
total costs were 21 million US dollars per 100 000 popu-
lation in the year 1993 (47% direct, 53% indirect costs).
The largest components were the direct costs of inpatient
care and indirect costs due to premature death (each
approximately 25% of the total). Trends showed a large
increase in direct costs ( + 9% per year, constant dollars).
Indirect costs stabilized or decreased slightly due to the
reduction of work losses.
Conclusions Today's medicine and preventive measures
have proven effective for ischaemic heart disease, although
such remedies have required increasingly large financial
resources. However, society benefits because indirect costs
decrease, although this gain does not compensate for all
direct costs.
(Eur Heart J 1997; 18: 1102-1109)
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Introduction
Changes in mortality patterns from ischaemic heart
diseases in Switzerland in past decades have been
characterized by a remarkable decrease in the mortality
of the population below the age of 65 years, while
overall ischaemic heart disease mortality stayed con-
stant'121. This has been observed in many other devel-
oped countries'31. The underlying processes involve, in
all probability, changes in lifestyle, preventive measures,
advanced diagnostic and therapeutic procedures in
medicine, and other unknown factors. The socio-
economic consequences of these changes in mortality,
however, have not been described in detail.
The objective of this study was to assess (i) the
trend in the economic costs of the disease as a result of
the more intensive utilization of health care services and
more frequent use of new technologies (higher direct
costs); and (ii) the changes in economic costs to society
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owing to the decreased mortality in the working popu-
lation (smaller work losses, i.e. lower indirect costs).
Methods
The entire cost-of-illness study was performed from a
societal perspective. The values of all major resource
elements consumed and of productivity lost were esti-
mated for patients afflicted by ischaemic heart disease
(ICD classes 410-414). The assessment of the economic
cost of ischaemic heart disease was prevalence-based. It
included direct and indirect costs of the illness, which
were estimated for the year 1993 (annual costs). The
results were contrasted with the analysis obtained
5 years earlier'41.
Direct costs of outpatient and inpatient care,
and inpatient rehabilitation
Outpatient care
The estimates of the direct costs elements (see Table 1)
were derived from information on the average number
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of patients in outpatient care (in the year of interest), the
frequency of physician contact, the interventions per
(average) physician visit (consultations, diagnostic tests),
the drugs prescribed (per visit) and the costs thereof.
Data provided by the IMS'5' allowed for a nation-
wide estimate of the number of ischaemic heart disease
patients and physician-prescribed drugs. IMS data
were based on nationwide surveys from representative
samples of physicians (stratified samples, n = 820).
There were no existing statistics on the type and
frequency of medical care in doctors' surgeries per
visit by ischaemic heart disease patients. Thus, written
interviews conducted by an expert panel of practising
physicians provided estimates of the average number of
visits (per year) by patients in the ICD classes 410-414
(first diagnosis) and the medical interventions (per visit).
The panel of 30 physicians was selected by the Chief
Medical Officers of the States, one eastern and one
western (Canton of St. Gallen and of Vaud), in which
the physicians were practising. GPs as well as specialists
(in internal medicine and cardiology), aged between
40 and 60 years, were questioned. Their information
could be verified, in part, by data obtained from the
IMS.
The costing of the office visits, individual labo-
ratory tests, chest X-rays etc. was based on the official
reimbursement tariffs in use throughout the country'61.
The reimbursement rates represent accurate proxies to
the real costs141. (The unsubsidized tariffs are agreed
upon by the medical associations, and insurers, and are
approved by the government.)
Reckoning the total annual costs followed the
general rule of: number of patients treated x frequency
of physician visits x number of interventions (per visit) x
costs per intervention x costs of drugs*.
Inpatient care
The database of the Swiss National Hospital Associ-
ation (VESKA)'71 was used to identify hospitalized cases,
their average length of stay, and the number of in-
hospital deaths (all with primary discharge diagnosis
ICD 410-414, sex- and age-specific). The statistics were
based on information from 45% of all hospitalizations in
the country such that extrapolation (to the population)
could be done without introducing large uncertainties.
The percentage of patients and the average
length of stay in critical care (in CCUs, cardiac care
units) of patients with acute myocardial infarction were
obtained from a special study analysing the treatment
schedules of ICD-410 cases in two Swiss States'81. The
study also contained information on the average per-
centage of patients referred to special rehabilitation after
acute myocardial infarction.
The number of major interventions carried out
were available from the Swiss Society of Cardiology
which regularly publishes the total number of procedures
performed in the country. In this study, those performed
most frequently i.e. coronary arteriographies, PTCAs
* Precise details available from the authors on request
Table 1 Major socio-economic cost components with
main elements of direct and indirect costs. Direct non-
medical costs are not listed
Direct costs
Direct medical costs
Outpatient care Costs of physician visits including
diagnostic test
Cost of drugs
Cost of emergency referral to hospital
Inpatient costs Cost of general care in hospital
including basic care, usual tests and
drugs, hotel services
Cost of critical care
Costs of frequent and costly
interventions (coronary
artenography, PTCA, CABG)
Cost of (inpatient) rehabilitation
Indirect costs
Productivity losses Due to morbidity
Due to disability; partial and total
Due to premature death
Psychosocial costs
PTCA = percutaneous transluminal coronary angioplasty;
CABG = coronary artery bypass grafting.
(percutaneous transluminal coronary angioplasty) and
CABGs (coronary artery bypass grafting)'9101 were
taken into account.
Information on individual cost elements were not
generally available but could be obtained by extrapo-
lating calculations carried out by the Cantonal Hospital
of St. Gallen, Switzerland (personal communication).
The cost structures of this medical centre were typical of
the majority of Swiss hospitals (treating ischaemic heart
disease patients'"1). Cost data on rehabilitation were
obtained directly from the administrators of the major
rehabilitation centres in Switzerland'121.
The following formula was used to calculate
total costs*: Inpatient costs = [number of patients x
average length of stay on the ward x cost of inpatient
day on the ward + number of patients in the CCU x
average length of stay in CCU x cost of CCU day] +
[number of procedures x cost of procedure].
Indirect costs due to morbidity, partial and
total disability, and premature death
The elements of indirect cost (Table 1) were evaluated
using the human capital approach. Thus, productivity
losses (to society) were calculated on the basis of the
incomes foregone, assuming that loss of productivity is
approximated by loss of wages'13'141. The current value
of lifetime earnings foregone due to premature death
was calculated using the generally accepted method of
discounting (with a discount rate of 4%).l'4]
The information relevant to the calculations of
indirect costs originated from the annual mortality fig-
ures by WHO'11, national statistics on disability due to
* Precise details available from the authors on request
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Table 2 Growth in use of health care services by ischaemic heart disease patients
(ICD 410-414) in Switzerland, standardized to a population oflO5. Number of office
visits, hospital discharges (first diagnosis of ischaemic heart disease), total number
of coronary angiographies, percutaneous transluminal coronary angioplasties
(PTCA), and coronary artery bypass grafts (CABG), together with the population in
Switzerland, from 1988 to 1993/S-7-910-17' are shown
Year
Office visits (per 105 of the population)
Hospital discharges (per 105 of the population)
Coronary angiography (per I05 of the population)
PTCA (per 105 of the population)
CABG (per 105 of the population)
Population in millions
1988
1475
493
ca 150
24
39
6-6
1990
1752
524
185
34
51
6-75
1993
1950
655
252
65
62
6-9
ICD 410-414'151, and information on absenteeism due to
ischaemic heart disease. Absenteeism resulting from
ischaemic heart disease could be estimated on the basis
of (sex-specific) data furnished by the National Railroad
Company, the SBB (personal communication). The SBB
employed about 37 000 workers, in all trades and pro-
fessional groups, representing approximately 1-5% of the
total labour force.
Information on partial and total disability
(number of cases, degrees of disability) was made avail-
able by the National Social Security office (National
Disability Insurance Office)1'5'. It is to be noted that
those data also comprised information on (non-salaried)
housewives afflicted by the disease who of course were
taken into account.
In addition, the national statistics on (age- and
sex-specific) income distributions (based on Social
Security payments being a fixed percentage of wages)
and on labour force participation rates'161 were intro-
duced into the calculations. When attaching a dollar
value to the work of housewives, the average income of
women (in the labour force) was used (for lack of a
generally accepted method of assessing). The national
statistics on (age- and sex-specific) mortalities due to all
causes (life tables) were also used'17'.
A straightforward approach (equal for men and
women, and in most cases ICD- and age-specific) was
used to calculate indirect morbidity costs*. Indirect costs
of (short-term) morbidity=average annual loss of work
days per member of labour force x total number of
labour force x average income per day, and indirect
costs of permanent (partial or total) disability = sum of
the products of [number of invalids of degree n x
disability degree n x average annual income x labour
force participation rate].
The algorithm used to obtain the value of future
earnings lost because of premature death took into
account that (i) the number of deaths due to ischaemic
heart disease depends on age (WHO mortality statistics);
(ii) incomes are a function of age (national income
* Precise details available from the authors on request
distribution); (iii) today's value of possible future
incomes is less than the nominal value (discounting with
a discount rate of 4%); (iv) patients dying of ischaemic
heart disease would not have necessarily lived for
another 10, 20 etc. more years, had they survived the
disease. They may have died from other causes in 10 or
20 years (evident from life tables); (v) patients surviving
the disease would not necessarily have returned to the
active working force; they may have been unemployed if
they would have lived longer (age distribution of labour
force participation rate). The algorithm is reproduced in
detail in the Appendix.
Gains in the number of potential life years due to
shifts in the mortality patterns were assessed, to illustrate
recent epidemiological developments, by reckoning the
differences in the potential life years lost, age- and sex-
specific, between 1988 and 1993. The potential life years
lost by each age group were given, using the customary
method, by the products of the number of premature
deaths x their average life expectancy (at that age).
Sensitivity analyses
Many of the cost evaluations were based on input data
subject to uncertainties or unknown variations. The
order of magnitude of the uncertainties could be given
accurately in some cases, approximately only in others.
It was therefore important to analyse the possible influ-
ences of the uncertainties on the final figures by sensi-
tivity analysis'18'. In particular, sensitivity of indirect
costs to changes in discount rates were evaluated by
varying the latter from 2% to 6%.
Results
Utilization
The volumes of health services utilization (by a popu-
lation remaining constant) grew significantly, as illus-
trated in Table 2. The rapid expansions are mirrored in
the enlarging direct costs as discussed below.
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Table 3 Number of potential life years lost per 1000 population, due to ischaemic
heart disease (1CD 410-414), for men and women in Switzerland, 1987188 vs 1993;
age-specific; together with differences (1993-1987). Negative differences in life years
lost represent gains in potential life years (bold figures). Note that some figures in the
lowest age groups are uncertain due to small size of samples
Men
1987
1993
Difference
Women
1987
1993
Difference
All
201
180
11-2
11-6
+0-4
25-34
11
1-3
+0-2
021
019
Potential
35-44
6-8
6-3
- 0 - 5
0-95
1-37
+ 0-4
life years
45-54
20-8
15-9
- 4 - 9
31
4-3
+ 1-2
lost per 1000
55-64
49-7
37-3
-12-4
10-9
9 0
- 1 - 9
population
65-74
87-9
79-5
-8 -4
36-2
32-1
- 4 1
75-84
108-4
103-3
- 5 1
73-6
72-1
- 1 - 5
>84 years
108-7
140-0
+ 31-3
95-7
118-2
+ 22-5
Epidemiological changes
Mortality in Switzerland due to ICD410-414 is low
compared with other industrialized countries1'1. The
pattern of its age distribution is very similar, however. It
is noteworthy that mortality decreased considerably
during the short period of 1988-1993, most markedly in
the 55- to 64-year-old-age group, while the overall
mortality stayed constant. Mortality in men of this age
declined from about 250 to 190 (per 100 000 popu-
lation), i.e. by approximately 25%. With women of the
same age, mortality decreased from approximately 46 to
37 (per 100 000 population), i.e. by approximately 20%.
It is significant that the improvements concern the
population active in the labour force. See Fig. 1.
Direct consequences of the shift in mortality
patterns are also evident when the losses in potential life
years are calculated (Table 3). With men, a gain is found
(survival gain) in that the potential life years lost have
decreased by close to 10% in the period from 1988 to
1993. The situation is different with women. At the ages
of 55-74 years, women lost fewer potential life years,
while younger and older age groups showed increased
losses. The sum of life years lost, in the case of Swiss
women overall, increased slightly.
10 000
100 -
JB'-S 1000
!§
So
s§
I
40 50 60 70 80
Age (years)
Figure 1 Mortality (per 100 000 population) due to
ischaemic heart diseases (ICD 410-414) in Switzerland,
for men and women, as a function of age; for the years
1988 and 1993. Semilogarithmic plot. =men in 1988;
=men in 1993; =women in 1988, =women
in 1993.
Economic costs of ischaemic heart disease
in Switzerland
The total costs of ischaemic heart disease patients (ICD
410-414) in Switzerland in 1993 amounted to 21 billion
Swiss Francs. This corresponded to US $ 1 -42 billion
(1993 dollars), taking into account the average exchange
rate in 1993 of 1-45 Swiss Francs per US S[l7]. In this
year, the Swiss population was 6-9 million. Thus, the
standardized costs were S21 million per 105 population.
The major cost components contributed approxi-
mately equal amounts to the total, i.e. the direct costs
were S 9-9 million per 105 population (47%), and the
indirect costs amounted to S 11-3 million per 105 popu-
lation (53% of the total). The individual cost elements
are listed in absolute and relative terms (percentages),
together with their possible ranges, in Table 4.
Among the dominant elements determining
direct costs, inpatient care was the most costly (with 57%
of all direct costs) while outpatient care was less (41%).
The largest element of indirect costs was due to prema-
ture deaths (46% of all indirect costs) while the contri-
bution of production losses due to morbidity and
disability were about equal (30% and 24% respectively).
The total sums could not all be analysed accord-
ing to sex, age and ICD group. The main reason was
that data on patients treated on an outpatient basis were
not grouped accurately enough into the ICD classes for
our analyses. Moreover, the work loss cases (indirect
cost due to morbidity) were not available in age-specific
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Table 4 Costs of ischaemic heart diseases, ICD 410-414, in Switzerland in 1993,
with direct and indirect cost components, in absolute and relative terms (of subtotals);
costs are given in standardized form and constant dollars (1993 US $ per 10s
population), together with their possible range of variation
Cost elements
Direct costs
Outpatient care
Inpatient care
Rehabilitation
Subtotal
Indirect costs
Due to morbidity
Due to disability
Due to premature death
Subtotal
Total: direct plus indirect costs
Ischaemic heart diseases costs
Estimate
($ million
4 1
5-6
015
9-9
3-4
2-7
5-2
11-3
21-2
Absolute
Range
per 105 population)
4 1-4-4
5-6-6-2
0-15-0-18
9-9-10-8
3-1-3-4
2-7-3-1
4-8-5-7
10-6-12-2
20-5-23
in 1993
Percentage
(% of subtotal)
41
57
2
100
30
24
46
100
form. Therefore, the details on relative contributions (to
the total sum) by the age groups and ICD classes could
not be worked out.
Uncertainties in the original data and their influ-
ence on the results were analysed based on extensive
sensitivity analyses. Costs of outpatient care were ini-
tially calculated conservatively, based on a low estimate
of the number of ischaemic heart disease patients. With
a (possible) 10% increase in patients, costs would grow
by 7-5%. Costs of inpatient care (also assessed conserva-
tively by taking into account the most frequent interven-
tions, only) depended directly on the costs per inpatient
day. If inpatient costs were 10% higher, total inpatient
care would also increase by 10%. Indirect costs due to
morbidity would vary directly with the computed work
days lost. If our initial and possibly high estimate of
total losses of work days was 10% too high, our cost
calculation would correspondingly be 10% too high.
Indirect costs due to disability were possibly underesti-
mated by approximately 15% (because of oblique distri-
bution of degrees of disability in the highest 'disability
class')- Indirect costs due to premature death would vary
with different discount rates. With a discount rate of 2%,
the costs would be 9% higher than shown above. With a
discount rate of 6%, costs would decrease by 7%.
Changes in costs of ischaemic heart disease
1988-1993
The analysis of changes in the costs of ischaemic heart
disease during the 5 year period from 1988 to 1993 was
based on an earlier illness costing study for the year
1987/88[4] as well as new calculations. The striking result
was that the two major components, i.e. direct and
indirect costs, showed significantly different behaviour.
12
H 10
ci5
o"3 8I f 6
If 4
0
-
- ^^ H^
[ = • •
Direct costs
•
•
^^B 1
Indirect costs
Figure 2 Cost development 1988-1993 for ischaemic
heart disease (ICD 410-414) in Switzerland. The strong
increase in direct costs and the decrease in indirect costs
are shown. The data shown are 'constant dollar' values.
• = 1988; D = 1993.
Direct costs grew rapidly while indirect costs receded
slightly (in real terms, cf. Table 5 and Fig. 2). In constant
dollars (i.e. in 1993 dollars), one finds an increase in
direct costs of +57% over the period of 5 years (or
ca + 9% per year) vs a small decrease in indirect costs of
approximately - 4% (ca. - 0-7% per year).
Direct costs increased at a disproportionately
high rate. Comparison with the expansion of total health
costs in the country (for all diagnoses) showed the
following. Total costs (in current dollar values) for
outpatient care (all diagnoses) grew at an annual rate of
approximately 6% per year[17), vs ca. 15% per year for
ischaemic heart disease. Costs of inpatient care for all
diseases increased by +9-5%[l9' per year, while ischaemic
heart disease patient cost increased at ca.+13-5%
per year.
The sum of indirect costs decreased by a small
amount. Costs due to morbidity and to premature death
both declined (by approximately — 2% per year). Some
of this gain was compensated for by the increasing costs
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Table 5 Comparison of costs of ischaemic heart diseases (ICH 410-414) in
Switzerland in 1988-1993 together with percentage changes, in constant (1993)
dollars, standardized per 10s population. The main cost elements of both direct and
indirect costs are also shown (costs of inpatient care including rehabilitation costs)
Development of costs of ischaemic heart diseases
Costs
1987/88 1993
(constant million $ per 105 population)
Increase
in real terms
(% per year)
Direct costs
Outpatient care
Inpatient care
Total direct costs
Indirect costs
Due to morbidity
disability
premature death
Total indirect costs
2-5
3-8
6-3
38
2-3
56
11-7
4-1
5-8
9-9
3-4
27
5-2
11-3
+ 57
- 4
due to disability (ca. +3% per year), however. Indirect
costs due to disability grew, probably because of the
survival of younger patients suffering from severe
ischaemic heart disease.
Discussion
Three significant processes were investigated in this
study: (i) the decrease in mortality of the young (ac-
companied by increases in mortality of the old); (ii) the
increasing financial resources consumed by the treat-
ment and care of ischaemic heart disease, the so-called
direct costs; and (iii) the decrease in the losses, or a gain
in production to society, as expressed by the indirect
costs.
Clearly, the advent of new medical interventions
and new treatment modalities, together with expanding
supply (e.g. more cardiological institutions as in the case
of Switzerland), have had strong effects on the direct
costs showing high rates of growth. This was under-
scored by the fact that inpatient care costs increased
significantly although the volume of inpatient days
decreased (shorter length of stay compensating for
higher numbers of hospitalized cases).
Concomitantly, decreases in mortality in the
population under 65 years of age resulted, first, in higher
prevalence (incidence staying approximately constant)
and, secondly, in lower work losses. The reduction in
productivity losses in turn resulted in a decrease in
indirect costs. It should be noted, however, that the
(relative) decrease in indirect cost is not sufficient to
compensate for the very rapid rise of direct economic
costs of the ischaemic heart diseases.
One important goal of medicine is to reduce
temporary and permanent morbidity due to ischaemic
heart disease and to postpone premature death. The
calculations presented show that the goal is reached in
parts. Society is gaining economically due to decreasing
productivity losses. It cannot be resolved, however, to
what extent medical care contributed to the develop-
ment. Assessments relating to this question were pub-
lished by Goldman'201. Analogous studies do not exist in
Switzerland.
The judgment of the significance of the message
conveyed by the estimate of ischaemic heart disease costs
obviously also depends on questions regarding the
power of the disease costing method as employed here,
and the quality of the data analysed.
Disease costing is an established field of health
economics. The main problems and arguments about
methodology have been largely resolved since the begin-
nings of formal economic investigations in the
1950s1'3'20'221. One possible point of contention may be
the use of the human capital approach. The method,
however, allows for estimates of economic losses to
society (and nothing more). As such, it has its estab-
lished position and has been the method of choice with
most health economists. Alternative approaches to in-
direct costs like those of 'willingness to pay' and 'will-
ingness to accept' methods suffer from the disadvantage
that they are difficult to apply and that the results
depend (among others) on the wealth of the individuals
questioned. This has been discussed extensively in the
literature1'3'141.
Completeness; comparisons
First, the cost elements evaluated in the study covered
the major areas in which (financial) resources are con-
sumed. Some of the additional elements were omitted.
Among the direct costs all those relating to residential
care (special technical aids, vocational rehabilitation and
the like) were not taken into account for lack of data
allowing for nationwide statistics (and estimates). The
same holds for direct cost of outpatient rehabilitation.
Among the elements of indirect costs time losses
(e.g. for travel to physicians office) or losses of income
and time of the family of the patient were omitted.
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Intangible (psycho-social) costs were not assessed,
either. Obviously, fear, suffering, and sorrow due to the
illness may weigh heavily. They affect the quality of life
of patients and their families significantly. While these
consequences of the disease can be rated, compared and
weighed against each other (e.g. for utility analyses) they
cannot be expressed in monetary terms. It was con-
sidered beyond the scope of this study to look into the
developments in this area.
The precision of some cost elements (e.g. out-
patient care, absenteeism) was not as high as with others
(e.g. inpatient care), but they could not be improved
because of lack of nationwide statistics. Sensitivity
analysis, while giving insight into the degrees of un-
certainty involved did not affect the final conclusion,
however.
The cost of ischaemic heart disease has been
investigated intensely in many countries for obvious
reasons. To our knowledge, however, there are no recent
studies on trends and analyses of direct vs indirect costs,
such as that by Rice et al.[22].
Nevertheless, Rice's and Scitovsky's work122'251
provide useful bases for special comparisons. In their
work the ratio of direct to indirect costs showed strong
increases. The reason was because direct costs of (all)
cardiovascular diseases rose more rapidly (by a factor of
3 in 8 years) than indirect costs which were growing
more slowly ( + 80% in 8 years). This differs from the
results of the current investigation, which covered a
later period in time, and related to Switzerland where
indirect cost stabilized or even decreased because of the
reduction in work loss.
Recently published studies had different end-
points in that resource utilization for specially selected
diagnostic groups by particular, special treatment
modalities were analysed'20'26"301. Our study differed in
that it was 'institution-oriented' and covered all medical
acts for all cases in the ICD 410-414 groups. Direct
comparisons could be quite misleading.
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Appendix
Algorithm for indirect costs
The indirect costs were equalled to the current value of
all future incomes foregone (Elo() by the ischaemic heart
disease cases dying prematurely, corresponding to the
sum of (the current values of all future) incomes (£,) lost
of the age groups in the working population. Formally:
£,o,= I NJXEJ
where A^=number of premature deaths at the agey (due
to ICD 410-414)
£y=current value of expected future earnings for-
gone by the ischaemic heart disease cases
dying at the agey".
The current value Ej of the expected incomes was
calculated as follows, per individual (dying prematurely)
at the age of j :
2s, (1+r)1
where sk = survival rate at the (average) age k
k=index of age group; kmax covers age group
56-65 years for men, 56-62 years for women
r= discount rate
ek=labour force participation rate at the (aver-
age) age k
Ik=average earnings of the age group A; in 10
years; multiplied by 0-5 in the first decade.
The second equation takes into account that
premature deaths occur, in the average, at the mid-age
of each age group.
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